Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology

2018 update of the APLAR recommendations for treatment of rheumatoid arthritis

(2019) Chak Sing Lau et al.   International Journal of Rheumatic Diseases

Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)

(2018) Yuko Kaneko et al.   ANNALS OF THE RHEUMATIC DISEASES

What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis

(2018) Emma Simpson et al.   HEALTH TECHNOLOGY ASSESSMENT

Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study

(2018) Yao-Min Hung et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

What does power Doppler signal indicate in rheumatoid synovitis? A point of view from synovial histopathology

(2018) Kuo-Lung Lai et al.   Journal of the Chinese Medical Association

Comparison of Ultrasound, Radiography, and Clinical Investigations in the Diagnosis of Early Rheumatoid Synovitis in Patients with Nonspecific Musculoskeletal Symptoms: A Multicenter Cross-Sectional Study

(2018) Ying-hua Zhang et al.   MEDICAL SCIENCE MONITOR

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

(2018) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Rheumatoid arthritis

(2018) Josef S. Smolen et al.   Nature Reviews Disease Primers

Nurses’ roles in the management of chronic inflammatory arthritis: a systematic review

(2018) Lion Vivienne et al.   RHEUMATOLOGY INTERNATIONAL

Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials

(2017) Arnaud Mazouyès et al.   JOINT BONE SPINE

Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review

(2017) Yi-Ming Chen et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial

(2017) Nicole P. C. Konijn et al.   RHEUMATOLOGY

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies

(2017) Xavier M Teitsma et al.   RHEUMATOLOGY

Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis

(2017) Jennifer Schenfeld et al.   RHEUMATOLOGY INTERNATIONAL

Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept

(2017) Shana M. Peper et al.   ARTHRITIS CARE & RESEARCH

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment

(2016) Iris M. Markusse et al.   ANNALS OF INTERNAL MEDICINE

Intramuscular versus ultrasound-guided intratenosynovial glucocorticoid injection for tenosynovitis in patients with rheumatoid arthritis: a randomised, double-blind, controlled study

(2016) Mads Ammitzbøll-Danielsen et al.   ANNALS OF THE RHEUMATIC DISEASES

Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial

(2016) T M Kuijper et al.   ANNALS OF THE RHEUMATIC DISEASES

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

(2016) Carina Götestam Skorpen et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial

(2016) Patrick Verschueren et al.   ANNALS OF THE RHEUMATIC DISEASES

Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions

(2016) Georg Schett et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

(2016) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis

(2016) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial

(2016) James Dale et al.   ANNALS OF THE RHEUMATIC DISEASES

Good practice in shared care for inflammatory arthritis

(2016) Mark P Lythgoe et al.   BRITISH JOURNAL OF GENERAL PRACTICE

The additional benefit of ultrasonography to 2010 ACR/EULAR classification criteria when diagnosing rheumatoid arthritis in the absence of anti-cyclic citrullinated peptide antibodies

(2016) Lanlan Ji et al.   CLINICAL RHEUMATOLOGY

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

(2016) Mette Julsgaard et al.   GASTROENTEROLOGY

Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug

(2016) Jacques-Eric Gottenberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review

(2016) Emeline Minichiello et al.   JOINT BONE SPINE

The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery

(2016) J. Widdifield et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and Outcome of Rapid Access Rheumatology Consultation: An Office-based Pilot Cohort Study

(2016) R. Puchner et al.   JOURNAL OF RHEUMATOLOGY

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial

(2016) Johannes W J Bijlsma et al.   LANCET

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

(2016) Josef S Smolen et al.   LANCET

Rheumatoid arthritis

(2016) Josef S Smolen et al.   LANCET

Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab

(2016) Yoshiya Tanaka et al.   Modern Rheumatology

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolution of Patient Decision-Making Regarding Medical Treatment of Rheumatoid Arthritis

(2016) Alexandra L. Mathews et al.   ARTHRITIS CARE & RESEARCH

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial

(2016) Espen A Haavardsholm et al.   BMJ-British Medical Journal

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial

(2016) Espen A Haavardsholm et al.   BMJ-British Medical Journal

Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients

(2016) Tarun S. Sharma et al.   Journal of the American Heart Association

Abatacept Therapy for Rheumatoid Arthritis in the Setting of Hepatitis C Infection

(2016) Tina Dewan Mahajan et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)

(2015) K Hørslev-Petersen et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

(2015) Jung-Yoon Choe et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis

(2015) A Richter et al.   ANNALS OF THE RHEUMATIC DISEASES

Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point

(2015) Daniel Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis

(2015) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study

(2015) Judith Haschka et al.   ANNALS OF THE RHEUMATIC DISEASES

Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial(STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)

(2015) Bruno Fautrel et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

(2015) Jeremy Sokolove et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

(2015) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

(2015) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

APLAR rheumatoid arthritis treatment recommendations

(2015) Chak Sing Lau et al.   International Journal of Rheumatic Diseases

Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis

(2015) Pi-Yueh Chang et al.   International Journal of Rheumatic Diseases

Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review

(2015) T. M. Kuijper et al.   JOURNAL OF RHEUMATOLOGY

A comparison of the ultrasonography images of the joints of patients with rheumatoid arthritis and the corresponding synovial histological findings

(2015) Asami Abe et al.   Modern Rheumatology

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis

(2015) Tsutomu Takeuchi et al.   Modern Rheumatology

Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis

(2015) Esperanza Naredo et al.   RHEUMATOLOGY

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

(2015) Sofie HM Manders et al.   ARTHRITIS RESEARCH & THERAPY

Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study

(2015) Cristiano S. Moura et al.   ARTHRITIS RESEARCH & THERAPY

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

(2015) N. van Herwaarden et al.   BMJ-British Medical Journal

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

(2015) N. van Herwaarden et al.   BMJ-British Medical Journal

When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations

(2014) Cécile Gaujoux-Viala et al.   Annals of the New York Academy of Sciences

A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial

(2014) J L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

(2014) Michael H Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study

(2014) T W J Huizinga et al.   ANNALS OF THE RHEUMATIC DISEASES

Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes

(2014) Adeline Ruyssen-Witrand et al.   ANNALS OF THE RHEUMATIC DISEASES

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis

(2014) Rene Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial

(2014) P Verschueren et al.   ANNALS OF THE RHEUMATIC DISEASES

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

(2014) P H de Jong et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

(2014) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

(2014) Jonas K Eriksson et al.   ANNALS OF THE RHEUMATIC DISEASES

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

(2014) J S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Arthritis patients’ motives for (not) wanting to be involved in medical decision-making and the factors that hinder or promote patient involvement

(2014) Ingrid Nota et al.   CLINICAL RHEUMATOLOGY

Value of ultrasonography for diagnosis of synovitis associated with rheumatoid arthritis

(2014) Hua Xiao et al.   International Journal of Rheumatic Diseases

Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial

(2014) F. Iannone et al.   JOURNAL OF RHEUMATOLOGY

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis

(2014) Paul Emery et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of Relapse After Discontinuation of Biologic Agents by Ultrasonographic Assessment in Patients With Rheumatoid Arthritis in Clinical Remission: High Predictive Values of Total Gray-Scale and Power Doppler Scores That Represent Residual Synovial

(2014) Taro Iwamoto et al.   ARTHRITIS CARE & RESEARCH

Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis

(2014) J. R. Curtis et al.   ARTHRITIS CARE & RESEARCH

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

(2014) Helga Radner et al.   ARTHRITIS RESEARCH & THERAPY

What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review

(2013) J A B van Nies et al.   ANNALS OF THE RHEUMATIC DISEASES

A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks

(2013) Debby den Uyl et al.   ANNALS OF THE RHEUMATIC DISEASES

Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project

(2013) Michaela A Stoffer et al.   ANNALS OF THE RHEUMATIC DISEASES

Shared care or nursing consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis outpatients with low disease activity—patient outcomes from a 2-year, randomised controlled trial

(2013) Jette Primdahl et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis

(2013) Alexandra N Colebatch et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

(2013) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

(2013) J L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Patients with Rheumatoid Arthritis

(2013) L. Aguilar-Lozano et al.   JOURNAL OF RHEUMATOLOGY

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

(2013) Josef S Smolen et al.   LANCET

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

(2013) Norihiro Nishimoto et al.   Modern Rheumatology

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

(2013) James R. O'Dell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Burden of disease in treated rheumatoid arthritis patients: Going beyond the joint

(2013) Maurizio Cutolo et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Glucocorticoid Dose Thresholds Associated With All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis

(2013) Inmaculada del Rincón et al.   Arthritis & Rheumatology

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

(2012) John D Isaacs et al.   ANNALS OF THE RHEUMATIC DISEASES

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

(2012) Jacqueline Detert et al.   ANNALS OF THE RHEUMATIC DISEASES

Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study

(2012) Aatke van der Maas et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

(2012) Monika Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

(2012) Larry W. Moreland et al.   ARTHRITIS AND RHEUMATISM

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

(2012) Ronald F van Vollenhoven et al.   LANCET

Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection

(2012) C. Dragonas et al.   RHEUMATOLOGY

Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery?

(2012) D. E. Feldman et al.   RHEUMATOLOGY

Immediate access rheumatology clinic: efficiency and outcomes

(2011) Miriam Gärtner et al.   ANNALS OF THE RHEUMATIC DISEASES

A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry

(2011) Lydia G Schipper et al.   ANNALS OF THE RHEUMATIC DISEASES

Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China

(2011) C. C. Mok et al.   ARTHRITIS AND RHEUMATISM

A comparison of ultrasound and clinical examination in the detection of flexor tenosynovitis in early arthritis

(2011) Ihsane Hmamouchi et al.   BMC MUSCULOSKELETAL DISORDERS

Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial

(2011) I. C. van Eijk et al.   RHEUMATOLOGY

The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study

(2011) D. Kyburz et al.   RHEUMATOLOGY

Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study

(2011) T. Y. Zhu et al.   RHEUMATOLOGY

Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection

(2011) Takao Nagashima et al.   RHEUMATOLOGY INTERNATIONAL

Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection

(2011) Amy M. Joseph   Therapeutic Advances in Musculoskeletal Disease

Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study

(2010) N. B. Klarenbeek et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

(2010) B. Saleem et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

(2010) Y. Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology

(2010) Chi Chiu Mok et al.   CLINICAL RHEUMATOLOGY

DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis

(2009) Y P M Goekoop-Ruiterman et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis

(2009) Olivier Brocq et al.   JOINT BONE SPINE